{
 "version": "2.2",
 "instance": {
  "asnd-20260331.htm": {
   "nsprefix": "asnd",
   "nsuri": "http://ascendispharma.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "asnd-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "asnd-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "definitionLink": {
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    }
   },
   "keyStandard": 155,
   "keyCustom": 76,
   "axisStandard": 20,
   "axisCustom": 5,
   "memberStandard": 22,
   "memberCustom": 23,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 132,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 523,
   "unitCount": 12,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 423,
    "http://xbrl.sec.gov/dei/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/CoverPage",
     "longName": "75000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
     "longName": "75010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "shortName": "Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "75020 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
     "longName": "75030 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_3a231070-4030-4551-888b-2f76f79cfd2c",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b902989b-2802-40f8-8d21-25e63b08c7b8",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "75040 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:AdjustmentsForNonCashConsiderationRegardingRevenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/GeneralInformation",
     "longName": "75050 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies",
     "longName": "75060 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimates",
     "longName": "75070 - Disclosure - Significant Accounting Judgments and Estimates",
     "shortName": "Significant Accounting Judgments and Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/SignificantEventsInTheReportingPeriod",
     "longName": "75080 - Disclosure - Significant Events in the Reporting Period",
     "shortName": "Significant Events in the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/Revenue",
     "longName": "75090 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShare",
     "longName": "75100 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformation",
     "longName": "75110 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPayment1",
     "longName": "75120 - Disclosure - Share-based Payment",
     "shortName": "Share-based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/ShareCapital",
     "longName": "75130 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/TreasuryShares",
     "longName": "75140 - Disclosure - Treasury Shares",
     "shortName": "Treasury Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities",
     "longName": "75150 - Disclosure - Financial Assets and Liabilities",
     "shortName": "Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/SubsequentEvents",
     "longName": "75160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies",
     "longName": "75170 - Disclosure - Summary of Material Accounting Policies (Policies)",
     "shortName": "Summary of Material Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodTables",
     "longName": "75180 - Disclosure - Significant Events in the Reporting Period (Tables)",
     "shortName": "Significant Events in the Reporting Period (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/RevenueTables",
     "longName": "75190 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareTable",
     "longName": "75200 - Disclosure - Earnings Per Share (Table)",
     "shortName": "Earnings Per Share (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentTables",
     "longName": "75210 - Disclosure - Share-based Payment (Tables)",
     "shortName": "Share-based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesTables",
     "longName": "75220 - Disclosure - Treasury Shares (Tables)",
     "shortName": "Treasury Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables",
     "longName": "75230 - Disclosure - Financial Assets and Liabilities (Tables)",
     "shortName": "Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail",
     "longName": "75240 - Disclosure - Significant Accounting Judgments and Estimates - Additional Information (Detail)",
     "shortName": "Significant Accounting Judgments and Estimates - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_06cf3478-da11-4dec-93c3-570ff62eb206",
      "name": "asnd:TaxEffectFromDeferredTaxAssetRecognized",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_06cf3478-da11-4dec-93c3-570ff62eb206",
      "name": "asnd:TaxEffectFromDeferredTaxAssetRecognized",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr",
     "longName": "75250 - Disclosure - Significant Events in the Reporting Period - Schedule of Income Taxes Recognized in Unaudited Condensed consolidated Interim statements of Profit or Loss (Details)",
     "shortName": "Significant Events in the Reporting Period - Schedule of Income Taxes Recognized in Unaudited Condensed consolidated Interim statements of Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails",
     "longName": "75260 - Disclosure - Significant Events in the Reporting Period - Schedule of Development in Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Significant Events in the Reporting Period - Schedule of Development in Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_8512f654-4fc1-40c3-80eb-88c63750e090",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8512f654-4fc1-40c3-80eb-88c63750e090",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails",
     "longName": "75270 - Disclosure - Significant Events in the Reporting Period - Schedule of Specification of Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Significant Events in the Reporting Period - Schedule of Specification of Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:TaxEffectOfTaxLosses",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:TaxEffectOfTaxLosses",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
     "longName": "75280 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)",
     "shortName": "Significant Events in the Reporting Period - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:PaymentForRepurchaseOfShares",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:PaymentForRepurchaseOfShares",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
     "longName": "75290 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:RevenueFromServicesAndClinicalSupply",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
     "longName": "75300 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9f04f177-da6b-4c08-ae86-cb745b960dc4",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
     "longName": "75310 - Disclosure - Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)",
     "shortName": "Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_affd397d-15a2-462c-a35c-94c4255f20f9",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfRevenueToCommercialProductsExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail",
     "longName": "75320 - Disclosure - Revenue - Additional Information (Detail)",
     "shortName": "Revenue - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e332ddbe-9ad5-4b1f-8e88-1559eb49724b",
      "name": "asnd:NumberOfCountriesCoveringAgreements",
      "unitRef": "U_Country",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e332ddbe-9ad5-4b1f-8e88-1559eb49724b",
      "name": "asnd:NumberOfCountriesCoveringAgreements",
      "unitRef": "U_Country",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail",
     "longName": "75330 - Disclosure - Earnings Per Share - Summary of Earnings and Share Data Used in the Basic and Diluted Earnings Per Share Calculation (Detail)",
     "shortName": "Earnings Per Share - Summary of Earnings and Share Data Used in the Basic and Diluted Earnings Per Share Calculation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail",
     "longName": "75340 - Disclosure - Earnings Per Share - Summary of Earnings and Share Data Used in the Basic and Diluted Earnings Per Share Calculation (Parenthetical) (Detail)",
     "shortName": "Earnings Per Share - Summary of Earnings and Share Data Used in the Basic and Diluted Earnings Per Share Calculation (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_5ac21d74-aa84-44d5-be96-f0b903ea37d4",
      "name": "asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5ac21d74-aa84-44d5-be96-f0b903ea37d4",
      "name": "asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformationAdditionalInformationDetail",
     "longName": "75350 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_950939aa-b79f-450b-8dbd-79d83bfdff6d",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
     "longName": "75360 - Disclosure - Share-based Payment - Additional Information (Details)",
     "shortName": "Share-based Payment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "U_DkkPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea6fb6c3-6945-4a8c-8e6f-7a84d85296cd",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
     "longName": "75370 - Disclosure - Share-based Payment - Summary Of Share Based Payment (Detail)",
     "shortName": "Share-based Payment - Summary Of Share Based Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_26ee5fd0-fd2f-4388-a190-97213634b958",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_26ee5fd0-fd2f-4388-a190-97213634b958",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
     "longName": "75380 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)",
     "shortName": "Share-based Payment - Schedule of Warrant Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_7de371d1-1f0d-4c48-9689-8b437aba8dc6",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7de371d1-1f0d-4c48-9689-8b437aba8dc6",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail",
     "longName": "75390 - Disclosure - Share Capital - Additional Information (Detail)",
     "shortName": "Share Capital - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail",
     "longName": "75400 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "shortName": "Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_8512f654-4fc1-40c3-80eb-88c63750e090",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8512f654-4fc1-40c3-80eb-88c63750e090",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
     "longName": "75410 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)",
     "shortName": "Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "longName": "75430 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)",
     "shortName": "Financial Assets and Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "asnd:FairValueOfRoyaltyFundingLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail",
     "longName": "75440 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)",
     "shortName": "Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "asnd:RoyaltyFundingLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fe02176b-bc94-4718-9965-8de29d0d960d",
      "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
     "longName": "75450 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)",
     "shortName": "Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_8512f654-4fc1-40c3-80eb-88c63750e090",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_21b90594-c061-4588-b358-20fa156d8b43",
      "name": "asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
     "longName": "75460 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "shortName": "Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "asnd:RoyaltyFundingLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa814e55-f82d-4253-bf91-045c8756a6b2",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "75470 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_8510d903-cb3f-4ee5-9b4b-5b35970643f1",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c34ebf5f-b9c1-499c-89f8-05a2fcb7b351",
      "name": "asnd:BorrowingsAndDerivativeLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20260331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "totalLabel": "Weighted average number of ordinary shares, diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Adjustments for amortisation expense"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for current tax of prior periods",
        "terseLabel": "Current tax, adjustments to prior periods"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r303"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax of prior periods",
        "terseLabel": "Deferred tax, recognition of previously unrecognized deferred tax assets"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property, plant and equipment",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments for increase (decrease) in deferred income including contract liabilities",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "asnd_AdjustmentsForNonCashConsiderationRegardingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AdjustmentsForNonCashConsiderationRegardingRevenue",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Non Cash Consideration Regarding Revenue",
        "documentation": "Adjustments for non cash consideration regarding revenue.",
        "negatedLabel": "Non-cash consideration relating to revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for non-cash items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share Based Compensation Expense",
        "terseLabel": "Share-based payment",
        "label": "Adjustments for share-based payments"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American depository shares [member]",
        "documentation": "American depository shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount",
        "label": "Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]",
        "documentation": "Antidilutive securities not included in diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]",
        "documentation": "Antidilutive securities not Included In diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "AsiaMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "periodStartLabel": "Assets at beginning of period",
        "periodEndLabel": "Assets at end of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r69",
      "r126",
      "r130",
      "r209",
      "r210",
      "r238"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value [member]",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r55",
      "r66",
      "r190",
      "r207",
      "r209"
     ]
    },
    "asnd_AveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "AveragePricePerShare",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Price Per Share",
        "documentation": "Average price per share.",
        "terseLabel": "Average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "totalLabel": "Total basic earnings (loss) per share",
        "terseLabel": "Basic earnings/(loss) per share",
        "verboseLabel": "Basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "asnd_BoardMembersOfGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BoardMembersOfGroupMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board members of group.",
        "label": "Board members of group [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "totalLabel": "Total borrowings",
        "terseLabel": "Borrowings (excluding lease liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsAndDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsAndDerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings And Derivative Liabilities",
        "label": "Borrowings And Derivative Liabilities",
        "documentation": "BorrowingsAndDerivativeLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsCalledForRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsCalledForRedemption",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings called for redemption",
        "documentation": "Borrowings called for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsConditionForRedemption": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsConditionForRedemption",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings condition for redemption",
        "label": "Borrowings Condition For Redemption",
        "documentation": "Borrowings condition for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsInArrearsDefaultPaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsInArrearsDefaultPaymentStartDate",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings in arrears default payment start date",
        "label": "Borrowings In Arrears Default Payment Start Date",
        "documentation": "Borrowings in arrears default payment start date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Borrowings interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, maturity"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "asnd_BorrowingsRedemptionPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsRedemptionPeriod",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings redemption period",
        "label": "Borrowings Redemption Period",
        "documentation": "Borrowings redemption period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsThresholdConsecutiveTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold consecutive trading days for redemption",
        "label": "Borrowings Threshold Consecutive Trading Days For Redemption",
        "documentation": "Borrowings threshold consecutive trading days for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsThresholdPercentageOfSalePricePerShareForRedemption",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold percentage of sale price per share for redemption",
        "label": "Borrowings Threshold Percentage Of Sale Price Per Share For Redemption",
        "documentation": "Borrowings threshold percentage of sale price per share for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "BorrowingsThresholdTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold trading days for redemption",
        "label": "Borrowings Threshold Trading Days For Redemption",
        "documentation": "Borrowings Threshold Trading Days For Redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r71",
      "r86",
      "r95",
      "r161",
      "r280",
      "r282",
      "r330"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 3.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at January 1",
        "periodEndLabel": "Cash and cash equivalents at March 31"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r62",
      "r162",
      "r232"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) financing activities",
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash flows from/(used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r44"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash flows from/(used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r44"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Cash flows from/(used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r44"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operations",
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash flows generated from/(used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets by category",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities by category",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r199"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r199"
     ]
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial assets [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial liabilities [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r182"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r182"
     ]
    },
    "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ChangesInDeferredTaxLiabilityAssetAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in deferred tax liability (asset) [abstract]",
        "terseLabel": "Development in deferred tax assets/(liabilities)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in working capital:",
        "label": "Changes in working capital [abstract]",
        "documentation": "Changes in working capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r70",
      "r80",
      "r145",
      "r185",
      "r211"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r70",
      "r80",
      "r145",
      "r185",
      "r211"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r114",
      "r115",
      "r137",
      "r138",
      "r220"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r114",
      "r115",
      "r137",
      "r138",
      "r220"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r110",
      "r111",
      "r203",
      "r205"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r110",
      "r111",
      "r203",
      "r205"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r137",
      "r138"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r137",
      "r138"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r188"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r188"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r211"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r211"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r187"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r187"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r216",
      "r251"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r216",
      "r251"
     ]
    },
    "asnd_ClassificationOfRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ClassificationOfRelatedPartyAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Axis]",
        "label": "Classification Of Related Party [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ClassificationOfRelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ClassificationOfRelatedPartyDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Domain]",
        "label": "Classification Of Related Party [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CollaborationPartnersAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "CollaborationPartnersAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration partners and license agreements [Member]",
        "label": "Collaboration partners and license agreements [Member]",
        "documentation": "Collaboration Partners and License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CollaborationsAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "CollaborationsAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborations and license agreements [Member]",
        "label": "Collaborations And License Agreements [Member]",
        "documentation": "Collaborations and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CommercialCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "CommercialCustomersMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Customers.",
        "label": "Commercial customers [Member]",
        "terseLabel": "Commercial customers [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that may be reclassified subsequently to profit or (loss):",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r60",
      "r184",
      "r192",
      "r222",
      "r254",
      "r277"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r256"
     ]
    },
    "asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Contractual Undiscounted Cashflow Of Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfFinancialBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Contractual Undiscounted Cashflow Of Financial Borrowings",
        "documentation": "Contractual undiscounted cashflow of financial borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfFinancialLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Lease Liabilities",
        "documentation": "Contractual undiscounted cashflow of Financial lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Liabilities",
        "documentation": "Contractual undiscounted cashflow of financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty funding liabilities",
        "label": "Contractual Undiscounted Cashflow of Royalty Funding Liabilities",
        "documentation": "Contractual undiscounted cashflow of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Contractual Undiscounted Cashflow Of Trade Payables And Other Payables",
        "documentation": "Contractual undiscounted cashflow of trade payables and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConversionPricePerShare",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Conversion Price Per Share",
        "documentation": "Conversion price per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionRatePerNote": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConversionRatePerNote",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion rate per note",
        "label": "Conversion Rate Per Note",
        "documentation": "Conversion rate per note."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleDebtCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConvertibleDebtCurrentAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt current abstract.",
        "label": "Convertible Debt Current [Abstract]",
        "terseLabel": "Convertible notes, due April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConvertibleNotesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes current.",
        "label": "Convertible Notes Current",
        "terseLabel": "Convertible notes current",
        "totalLabel": "Convertible notes current"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConvertibleOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible ordinary shares",
        "documentation": "Convertibleordinaryshares",
        "terseLabel": "Convertible ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConvertibleSeniorNotes",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtAmortisedCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Senior Notes",
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes [Member]",
        "documentation": "Convertible senior notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r263"
     ]
    },
    "asnd_CostsOfCapitalIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "CostsOfCapitalIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of capital increase",
        "label": "Costs of capital increase (decrease)",
        "documentation": "Costs of capital increase (decrease)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current and deferred tax relating to items credited (charged) directly to equity",
        "totalLabel": "Aggregate current and deferred tax relating to items credited (charged) directly to equity",
        "terseLabel": "Income tax on equity transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate current and deferred tax relating to particular items that are charged or credited directly to equity, for example: (a) an adjustment to the opening balance of retained earnings resulting from either a change in accounting policy that is applied retrospectively or the correction of an error; and (b) amounts arising on initial recognition of the equity component of a compound financial instrument. [Refer: Deferred tax relating to items credited (charged) directly to equity; Retained earnings; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r170"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r243",
      "r277"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "asnd_ConvertibleNotesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "totalLabel": "Total current financial assets",
        "label": "Current financial assets",
        "terseLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail2": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current financial liabilities",
        "label": "Current financial liabilities",
        "terseLabel": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "negatedLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r244",
      "r277"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current prepayments",
        "terseLabel": "Prepayments",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "totalLabel": "Total current provisions",
        "terseLabel": "Provisions",
        "label": "Current provisions",
        "periodStartLabel": "Beginning balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax (expense)/income"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r302"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "totalLabel": "Current tax expense (income) and adjustments for current tax of prior periods"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax on profit/(loss) for the year",
        "label": "Current tax expense (income) and adjustments for current tax of prior periods [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "terseLabel": "Income tax payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r309",
      "r311"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DE",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "country_DK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DK",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denmark [member]",
        "label": "DENMARK"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences, assets",
        "label": "Deductible temporary differences for which no deferred tax asset is recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174"
     ]
    },
    "asnd_DeferredFaxAssetsLiabilitiesForeignExchangeTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DeferredFaxAssetsLiabilitiesForeignExchangeTranslation",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation",
        "label": "Deferred Fax Assets/(liabilities) Foreign Exchange Translation",
        "documentation": "Deferred fax assets/(liabilities) foreign exchange translation."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DeferredTaxAssetNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DeferredTaxAssetNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset, not recognized.",
        "label": "Deferred tax asset not recognized",
        "terseLabel": "Deferred tax asset, not recognized",
        "negatedLabel": "Deferred tax assets, not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets",
        "negatedLabel": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r175",
      "r237",
      "r239"
     ]
    },
    "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets and liabilities [abstract]",
        "terseLabel": "Classified in the statement of financial position",
        "verboseLabel": "Deferred tax assets/(liabilities)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "terseLabel": "Deferred income tax (expense)/income, through profit or loss"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r176"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r175",
      "r237",
      "r239"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "netLabel": "Net deferred tax liability (asset)",
        "periodStartLabel": "January 1,",
        "periodEndLabel": "March 31,",
        "verboseLabel": "Total deferred tax assets/(liabilities) at March 31",
        "totalLabel": "Total deferred tax assets/(liabilities) at March 31"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r175"
     ]
    },
    "asnd_DeferredTaxMovementForTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DeferredTaxMovementForTheYear",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Movement for The Year",
        "documentation": "Deferred tax movement for the year.",
        "terseLabel": "Deferred tax, movement for the period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax (expense)/income, through equity",
        "label": "Deferred tax relating to items credited (charged) directly to equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r170"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.",
        "terseLabel": "Remeasurement recognized in finance (income) or expense"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueSettled",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Settled",
        "terseLabel": "Settled",
        "documentation": "Derivative financial liabilities at fair value settled."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueTransfered",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfered",
        "label": "Derivative Financial Liabilities at Fair Value Transfered",
        "documentation": "Derivative financial liabilities at fair value transfered."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r281",
      "r290",
      "r296"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes and Derivative Liabilities",
        "label": "Description Of Accounting Policy For Convertible Notes And Derivative Liabilities [Policy Text Block]",
        "documentation": "Description of accounting policy for convertible notes and derivative liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "verboseLabel": "New and Amended Standards and Interpretations",
        "terseLabel": "New and Amended IFRS Accounting Standards and Interpretations"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r164"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting requirements for share-based payment arrangement",
        "terseLabel": "Description of vesting",
        "verboseLabel": "Vesting conditions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r193"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "totalLabel": "Total diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "asnd_DilutedEarningsPerShareReported": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DilutedEarningsPerShareReported",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings per share, reported",
        "documentation": "Diluted earnings per share, reported.",
        "terseLabel": "Diluted earnings/(loss) per share",
        "verboseLabel": "Diluted earnings per share"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DilutiveEffectOfWarrantsAndRestrictedShareUnitsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DilutiveEffectOfWarrantsAndRestrictedShareUnitsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Effect Of Warrants And Restricted Share Units On Weighted Average Number Of Ordinary Shares",
        "documentation": "Dilutive Effect Of Warrants And Restricted Share Units On Weighted Average Number Of Ordinary Shares.",
        "terseLabel": "Dilution effects from warrants and RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Marketable securities",
        "label": "Disclosure Detailed Information About Marketable Securities [Text Block]",
        "documentation": "Disclosure detailed information about marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "verboseLabel": "Significant Accounting Judgments and Estimates"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the changes in accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r166"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r216",
      "r251"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Earnings Per Share"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "asnd_DisclosureOfEmployeeCompensationCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfEmployeeCompensationCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of employee compensation costs [abstract]",
        "documentation": "Disclosure of employees compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r211"
     ]
    },
    "asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Financial Assets And Liabilities [text block]",
        "documentation": "Disclosure Of Financial Assets And Liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Liabilities",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r109",
      "r116",
      "r195"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r228"
     ]
    },
    "asnd_DisclosureOfGeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfGeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of general information.",
        "label": "Disclosure of General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from external customers (geographical)",
        "label": "Disclosure of geographical areas [abstract]",
        "verboseLabel": "Revenue (geographical)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfHoldingOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Abstract]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfHoldingOfTreasurySharesLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Line Items]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfHoldingOfTreasurySharesTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Table]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfInformationAboutTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfInformationAboutTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasuryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Disclosure Of Information About Treasury Shares Explanatory",
        "documentation": "Disclosure of information about treasury shares explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r206"
     ]
    },
    "asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movements in Level 3 Fair Value Measurements",
        "label": "Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]",
        "documentation": "Disclosure of movements in level 3 fair value measurements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r168"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "verboseLabel": "Summary of Weighted Average Exercise Prices and Movements in Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [line items]",
        "label": "Disclosure of operating segments [line items]",
        "verboseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfPerformanceObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of performance obligations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReclassificationsOrChangesInPresentationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change to Presentation of Borrowings",
        "label": "Disclosure of reclassifications or changes in presentation [text block]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r218",
      "r227"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "asnd_DisclosureOfRevenueToCommercialCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfRevenueToCommercialCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Revenue to Commercial Customers Explanatory",
        "documentation": "Disclosure of revenue to commercial customers explanatory.",
        "terseLabel": "Schedule of Revenue Attributable to Commercial Products"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfRevenueToCommercialProductsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfRevenueToCommercialProductsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue From Sale of Commercial Products",
        "label": "Disclosure Of Revenue To Commercial Products Explanatory",
        "documentation": "Disclosure of revenue to commercial products explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfRoyaltyFundingLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Funding Liabilities",
        "label": "Disclosure Of Royalty Funding Liabilities Explanatory",
        "documentation": "Disclosure of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of segment revenues by destination of major customers explanatory.",
        "label": "Disclosure of segment revenues by destination of major customers explanatory",
        "terseLabel": "Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r217",
      "r252"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPayment1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based Payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Hierarchy",
        "label": "Disclosure of Summary of Fair Value Hierarchy [Table Text Block]",
        "documentation": "Disclosure of summary of fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Disclosure Of Summary Of Significant Accounting Policy Explanatory",
        "documentation": "Disclosure of summary of significant accounting policy.",
        "verboseLabel": "Summary of Material Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Summary of Tax on Profit/Loss and Deferred Tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r177"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r194"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r182"
     ]
    },
    "asnd_DisclosureOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of treasury shares.",
        "label": "Disclosure of treasury shares [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Holding of Treasury Shares",
        "label": "Disclosure of treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of voluntary change in accounting policy [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfWarrantActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DisclosureOfWarrantActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrant Activity [line items]",
        "label": "Disclosure Of Warrant Activity [line items]",
        "documentation": "Disclosure Of Warrant Activity [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DistributableEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "DistributableEquity",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributable equity",
        "label": "Distributable equity",
        "documentation": "Distributable equity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EarningsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "EarningsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings [abstract]",
        "documentation": "Earnings.",
        "terseLabel": "Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Summary of Earnings and Share Data Used in the Basic and Diluted Earnings Per Share Calculation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on balances held in foreign currencies",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "asnd_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and consultants.",
        "label": "Employees and Consultants [Member]",
        "terseLabel": "Employees and consultants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Balance of equity",
        "terseLabel": "Balance of equity",
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity",
        "periodEndLabel": "Equity",
        "label": "Equity",
        "verboseLabel": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r66",
      "r67",
      "r69",
      "r183",
      "r191",
      "r209",
      "r210",
      "r219",
      "r238",
      "r246"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EuropeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe [member]",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EventsAfterReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "EventsAfterReportingPeriodMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After Reporting Period [Member]",
        "documentation": "Events after reporting period.",
        "terseLabel": "Events After Reporting Period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ExchangeRateForPercentageOfNetSalesToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate for percentage of net sales to royalty payment.",
        "label": "Exchange Rate For Percentage Of Net Sales To Royalty Payment",
        "terseLabel": "Net revenue from sales interest payment in percentage in exchange for funding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ExchangeRateForPercentageOfRevenueToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate for percentage of revenue to royalty payment.",
        "label": "Revenue interest payment in percentage in exchange for funding",
        "terseLabel": "Revenue interest payment in percentage in exchange for funding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation costs",
        "label": "Expense from share-based payment transactions with employees"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "asnd_FairValueHierarchyCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "FairValueHierarchyCarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Fair Value Hierarchy Carrying Amount [member]",
        "documentation": "Fair value hierarchy carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "FairValueOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Convertible Notes",
        "label": "Fair Value of Convertible Notes",
        "documentation": "Fair value of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "FairValueOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of royalty funding liabilities",
        "label": "Fair Value of Royalty Funding Liabilities",
        "documentation": "Fair value of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance expenses",
        "terseLabel": "Reversal of finance expenses",
        "label": "Finance costs",
        "negatedLabel": "Finance expenses"
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses paid",
        "label": "Finance costs paid, classified as operating activities"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reversal of finance income",
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income received",
        "label": "Finance income received, classified as operating activities"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "terseLabel": "Financial assets",
        "periodStartLabel": "Financial assets at beginning of period",
        "periodEndLabel": "Financial assets at end of period",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r107",
      "r108",
      "r110",
      "r203",
      "r204",
      "r205",
      "r289"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial assets measured at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r197"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r139",
      "r200"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCost",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities measured at amortized cost",
        "label": "Financial liabilities at amortised cost",
        "totalLabel": "Financial liabilities measured at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r198"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, class [member]",
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r139",
      "r200"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]",
        "terseLabel": "Financial liabilities at fair value, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities measured at fair value through profit or loss",
        "label": "Financial liabilities at fair value through profit or loss",
        "totalLabel": "Financial liabilities measured at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r196"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial liabilities measured at fair value through profit or loss [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r196"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate [Member]",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "asnd_ForeignCurrencyConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ForeignCurrencyConversionOptionMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Conversion Option [Member]",
        "documentation": "Foreign Currency Conversion Option."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "FundingReceivedInExchange",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding received",
        "verboseLabel": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange.",
        "terseLabel": "Funding received in exchange"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchangeOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "FundingReceivedInExchangeOfRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange of royalty payments.",
        "terseLabel": "Funding received in exchange of royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on change in fair value of derivatives",
        "terseLabel": "Gains (losses) on change in fair value of derivatives",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r266",
      "r284",
      "r287",
      "r300"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r266",
      "r284",
      "r287",
      "r300"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r301"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r301"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Gross profit",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r201"
     ]
    },
    "ifrs-full_HedgingInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgingInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r201"
     ]
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "negatedLabel": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r178",
      "r262"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncomeStatementAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement [Axis].",
        "label": "Income Statement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncomeStatementMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement.",
        "label": "Income Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfIncomeTaxesRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOr",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax income (expense)",
        "totalLabel": "Total tax expense (income)",
        "label": "Tax expense (income)",
        "negatedLabel": "Income taxes (expenses)",
        "verboseLabel": "Income tax (expense)",
        "terseLabel": "Total tax on profit/(loss) for the period",
        "netLabel": "Reversal of income taxes"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r19",
      "r64",
      "r125",
      "r169",
      "r172",
      "r173",
      "r259"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfDevelopmentInDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax (expense)/income, through other comprehensive income",
        "label": "Income tax relating to components of other comprehensive income",
        "totalLabel": "Aggregated income tax relating to components of other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r171",
      "r260"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes refund (paid)",
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes received/(paid)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r269"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Increase/(decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r162"
     ]
    },
    "asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "terseLabel": "Increase decrease in derivative financial liabilities fair value",
        "label": "Increase Decrease In Derivative Financial Liabilities Fair Value",
        "documentation": "Increase decrease in derivative financial liabilities fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in share capital",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In treasury shares acquired from third parties.",
        "label": "Increase Decrease In Treasury Shares Acquired From Third Parties",
        "verboseLabel": "Acquired from third-parties (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in treasury shares transferred under stock incentive program.",
        "label": "Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program",
        "terseLabel": "Transferred under stock incentive programs (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "terseLabel": "Capital increase"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "asnd_IncreaseInRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncreaseInRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in Right of Use Assets",
        "documentation": "Increase in right of use assets.",
        "terseLabel": "Increase in right-of-use"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreasedLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "IncreasedLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increased lease liability",
        "documentation": "Increased lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets and goodwill",
        "periodEndLabel": "Intangible assets and goodwill at end of period",
        "periodStartLabel": "Intangible assets and goodwill at beginning of period",
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current inventories",
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r160",
      "r231",
      "r309"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount of equity method investment",
        "label": "Investments accounted for using equity method",
        "totalLabel": "Total investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r127",
      "r208",
      "r230"
     ]
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in associates reported in separate financial statements",
        "terseLabel": "Investments in associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total issued capital",
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r312"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 to 5 years [member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r291",
      "r295"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 5 years [member]",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r295"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtAmortisedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r32",
      "r67",
      "r186",
      "r210"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r186",
      "r210"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r210"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r210"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Liabilities",
        "totalLabel": "Total liabilities",
        "periodStartLabel": "Liabilities at beginning of period",
        "periodEndLabel": "Liabilities at end of period",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r69",
      "r126",
      "r131",
      "r209",
      "r210",
      "r238"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses",
        "label": "Licence fee income"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity risk [member]",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r288"
     ]
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current portion of non-current borrowings",
        "terseLabel": "Borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorCustomersDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "asnd_MarketableSecuritiesExplanatory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MarketableSecuritiesExplanatory",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Explanatory",
        "documentation": "Marketable securities explanatory.",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketingApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MarketingApprovalMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing Approval [Member]",
        "documentation": "Marketing Approval."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MaturityAnalysisForFinancialLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Maturity Analysis For Financial Liabilities",
        "label": "Maturity Analysis For Financial Liabilities [Text Block]",
        "documentation": "Maturity analysis for financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r81",
      "r82",
      "r83",
      "r84",
      "r86",
      "r91",
      "r101",
      "r113",
      "r140",
      "r143",
      "r148",
      "r151",
      "r202",
      "r242",
      "r267",
      "r292"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r81",
      "r82",
      "r83",
      "r84",
      "r86",
      "r91",
      "r101",
      "r140",
      "r143",
      "r148",
      "r151",
      "r202",
      "r242",
      "r267",
      "r292",
      "r294"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r66",
      "r190",
      "r209"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r66",
      "r190",
      "r209"
     ]
    },
    "asnd_MilestonesRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MilestonesRevenue",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestones Revenue",
        "documentation": "Milestones revenue.",
        "terseLabel": "Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MultipleOfPurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple Of Purchase Price, Were Royalty Payment Will Cease",
        "documentation": "Multiple of purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple of the Purchase Price, were Royalty Payment will cease",
        "documentation": "Multiple of the purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred tax assets/(liabilities)",
        "label": "Net deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "asnd_NetSettlementUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NetSettlementUnderStockIncentivePrograms",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net settlement under stock incentive programs",
        "documentation": "Net settlement under stock incentive programs.",
        "terseLabel": "Net settlement under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NewShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NewShareRepurchaseProgramMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Share Repurchase Program [Member]",
        "documentation": "New share repurchase program.",
        "terseLabel": "New share repurchase program [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NonCashGainRecognizedOnOwnershipInterestInAssociate",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Gain Recognized On Ownership Interest In Associate",
        "documentation": "Non cash gain recognized on ownership interest in associate.",
        "terseLabel": "Non-cash gain recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r168"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r168"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r243",
      "r277"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial assets",
        "label": "Non-current financial assets",
        "terseLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail2": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial liabilities",
        "label": "Non-current financial liabilities",
        "terseLabel": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r244",
      "r277"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America [member]",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year [member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r91",
      "r146",
      "r149",
      "r240",
      "r292",
      "r295"
     ]
    },
    "ifrs-full_NotesAndDebenturesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotesAndDebenturesIssued",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and debentures issued",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Carrying amount of convertible notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of notes and debentures issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "asnd_NovoNordiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NovoNordiskMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novo Nordisk.",
        "label": "Novo Nordisk [member]",
        "terseLabel": "Novo Nordisk [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfCommercialCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfCommercialCustomers",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial customers.",
        "label": "Number of commercial customers",
        "terseLabel": "Number of commercial customers"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfCountriesCoveringAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfCountriesCoveringAgreements",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of countries covering agreements",
        "documentation": "Number of countries covering agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "verboseLabel": "Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r328"
     ]
    },
    "asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfOrdinaryShareRelatedToRepurchaseOfShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Ordinary Share Related to Repurchase of Shares",
        "documentation": "Number of ordinary share Related to repurchase of shares.",
        "terseLabel": "Number of ordinary share Related to repurchase of shares"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOrdinarySharesRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfOrdinarySharesRepurchased",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Ordinary Shares Repurchased",
        "documentation": "Number of ordinary shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised during the period",
        "terseLabel": "Vested at the reporting date",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "verboseLabel": "Specified by vesting year"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited during the period",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "negatedPeriodStartLabel": "Beginning balance",
        "negatedPeriodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled during the period",
        "label": "Number Of Other Equity Instruments Settled In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments settled in share based payment arrangement.",
        "negatedLabel": "Settled during the period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred during the period",
        "label": "Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments transferred in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Number of other equity instruments vested in share-based payment arrangement",
        "documentation": "Number of other equity instruments vested in share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfReportableOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfReportableOperatingSegments",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of reportable operating segments",
        "documentation": "Number of reportable operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number of shares [abstract]",
        "documentation": "Number of shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r212",
      "r247"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total number of shares issued",
        "terseLabel": "Number of shares issued",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodStartLabel": "Number of shares outstanding at beginning of period",
        "periodEndLabel": "Number of shares outstanding at end of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r214",
      "r249"
     ]
    },
    "asnd_NumberOfTreasurySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfTreasurySharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Treasury Shares Outstanding",
        "documentation": "Number of treasury shares outstanding.",
        "periodStartLabel": "January 1, 2026 (Holding)",
        "periodEndLabel": "March 31, 2026 (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants outstanding",
        "documentation": "Number of warrants outstanding.",
        "label": "Number of warrants outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_OfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "OfficeFacilityMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office facility.",
        "label": "Office Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translating foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r261"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "verboseLabel": "Other comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) for the period, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "totalLabel": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r235"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "asnd_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current liabilities abstract.",
        "label": "Other Current Liabilities [Abstract]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311"
     ]
    },
    "ifrs-full_OtherFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtAmortisedCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities",
        "terseLabel": "Other liabilities (excluding indirect tax, and employee related payables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other non-current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables (excluding indirect tax receivables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue",
        "terseLabel": "Other revenue"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Share nominal value",
        "terseLabel": "Nominal value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r213",
      "r248"
     ]
    },
    "asnd_PaymentForRepurchaseOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PaymentForRepurchaseOfShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for repurchase of shares",
        "label": "Payment For Repurchase Of Shares",
        "documentation": "Payment for repurchase of shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PaymentOfWithholdingTaxesUnderStockIncentivePrograms",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Withholding Taxes Under Stock Incentive Programs",
        "documentation": "Payment of withholding taxes under stock incentive programs.",
        "negatedLabel": "Payment of withholding taxes under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PaymentTermOfCustomers": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PaymentTermOfCustomers",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Term Of Customers",
        "label": "Payment Term Of Customers",
        "documentation": "Payment term of customers."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PaymentsReceivedUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PaymentsReceivedUnderFinanceLeases",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received under finance leases",
        "label": "Payments Received Under Finance Leases",
        "documentation": "Payments received under finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedLabel": "Payments to acquire or redeem entity's shares",
        "negatedTerseLabel": "Acquisition of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue",
        "terseLabel": "Perentage of sale to commercial products"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities",
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities",
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PercentageOfVestingRightsForShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting rights for share-based payment arrangement.",
        "label": "Percentage of vesting rights for share-based payment arrangement",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r142"
     ]
    },
    "ifrs-full_PerformanceObligationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PerformanceObligationsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r142"
     ]
    },
    "asnd_PerformanceStockUnitProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PerformanceStockUnitProgramMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock unit program member.",
        "label": "Performance Stock Unit Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance stock units."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares",
        "documentation": "Potential conversion of convertible senior notes into number of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreviouslyStatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PreviouslyStatedMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously stated [member]",
        "terseLabel": "Previously reported [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r49",
      "r163",
      "r165",
      "r167",
      "r223"
     ]
    },
    "asnd_PriorityReviewVoucherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PriorityReviewVoucherMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Priority Review Voucher [Member]",
        "documentation": "Priority Review Voucher."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Proceeds from borrowings",
        "verboseLabel": "Net proceeds from borrowings",
        "negatedLabel": "Net proceeds from borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of warrants",
        "terseLabel": "Net proceeds from exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance Of Notes",
        "label": "Proceeds from issue of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from follow-on public offering"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds after deduting offering expenses",
        "label": "Proceeds From Royalty Funding Liabilities Excluding Offering Expenses",
        "documentation": "Proceeds from royalty funding liabilities excluding offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales of intangible assets, classified as investing activities",
        "terseLabel": "Proceeds from sales of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property, plant and equipment",
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities",
        "verboseLabel": "Proceeds from disposal of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of marketable securities",
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r283",
      "r299"
     ]
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r283",
      "r299"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net profit/(loss) for the period",
        "label": "Profit (loss)",
        "verboseLabel": "Net profit/(loss) for the period",
        "totalLabel": "Net profit/(loss) for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r126",
      "r129",
      "r184",
      "r192",
      "r224",
      "r253",
      "r277",
      "r286"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share",
        "terseLabel": "Net profit/(loss) attributable to ordinary equity holders of the parent for the purposes of basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Profit/(loss) before tax"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r297",
      "r298",
      "r306",
      "r307"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating profit/(loss)"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r340"
     ]
    },
    "asnd_ProfitLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ProfitLossMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss.",
        "label": "Profit Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property, plant and equipment",
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r179",
      "r229"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Percentage owned"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r54"
     ]
    },
    "asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets and property, plant and equipment",
        "documentation": "Purchase of intangible assets and property, plant and equipment.",
        "negatedLabel": "Acquisition of intangible assets and property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "terseLabel": "Acquisition of treasury shares (Note 9)",
        "negatedLabel": "Acquisition of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "asnd_RSUNetSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RSUNetSettlementMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Net Settlement [member]",
        "documentation": "RSU net settlement.",
        "terseLabel": "RSU Net Settlement [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r71",
      "r86",
      "r95",
      "r161",
      "r280",
      "r282",
      "r330"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r71",
      "r86",
      "r95",
      "r161",
      "r280",
      "r282",
      "r330"
     ]
    },
    "ifrs-full_ReceivablesFromRentalOfProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReceivablesFromRentalOfProperties",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease receivable",
        "label": "Receivables from rental of properties",
        "verboseLabel": "Lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables arising from the rental of properties. Property is land or a building - or part of a building - or both."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in deferred tax liability (asset) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "asnd_RepurchaseOfSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RepurchaseOfSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of Shares Value",
        "documentation": "Repurchase of shares value.",
        "terseLabel": "Repurchase of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development expenses",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r189"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Foreign Currency Translation Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r180",
      "r308"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Share-based Payment Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "asnd_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of world.",
        "label": "Rest of world [member]",
        "terseLabel": "Rest of World [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r49",
      "r85",
      "r163",
      "r165",
      "r167",
      "r223",
      "r335"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Prior Periods Estimates and Assumptions [Member]",
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units [member]",
        "terseLabel": "RSUs"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "asnd_RestrictedStockUnitsAndPerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units and Performance Stock Unit [Member]",
        "documentation": "Restricted stock units and performance stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r308"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r49",
      "r163",
      "r165",
      "r167",
      "r223"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "totalLabel": "Total revenue",
        "label": "Revenue"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r98",
      "r124",
      "r128",
      "r132",
      "r133",
      "r135",
      "r257",
      "r277",
      "r306",
      "r307"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Operating Segments [abstract]",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Recognized as revenue",
        "verboseLabel": "Revenue recognized for YUVIWEL"
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r141"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Commercial products",
        "verboseLabel": "Revenue from commercial products"
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "asnd_RevenueFromServicesAndClinicalSupply": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RevenueFromServicesAndClinicalSupply",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Services and Clinical Supply",
        "documentation": "Revenue from services and clinical supply.",
        "terseLabel": "Services and clinical supply"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RevenueTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [table]",
        "documentation": "Revenue table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodStartLabel": "Right-of-use assets at beginning of period",
        "periodEndLabel": "Right-of-use assets at end of period",
        "terseLabel": "Right-of-use asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r79",
      "r144"
     ]
    },
    "asnd_RoyaltiesAndMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltiesAndMilestonesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and milestones.",
        "label": "Royalties and Milestones [Member]",
        "terseLabel": "Royalties And Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyFundingLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtAmortisedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty funding liabilities",
        "documentation": "Royalty funding liabilities.",
        "terseLabel": "Royalty funding liabilities",
        "verboseLabel": "Carrying amount of royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentBeginningPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyPaymentBeginningPeriod",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment beginning period.",
        "label": "Royalty payment beginning period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentEndingPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyPaymentEndingPeriod",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment ending period.",
        "label": "Royalty Payment Ending Period",
        "terseLabel": "Royalty payment ending period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyPharmaMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma.",
        "label": "Royalty Pharma [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyPharmaUnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma U.S. Skytrofa [member]",
        "documentation": "Royalty Pharma United States Skytrofa.",
        "label": "Royalty Pharma United States Skytrofa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "RoyaltyPharmaUnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty pharma united states yorvipath.",
        "label": "Royalty Pharma United States Yorvipath [Member]",
        "terseLabel": "Royalty Pharma U.S. Yorvipath [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock.",
        "label": "Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock.",
        "label": "Sale Of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Transfer under stock incentive programs"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "asnd_SalesRebatesAndProductReturnsInUSMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SalesRebatesAndProductReturnsInUSMarketMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales rebates and product returns in U.S. market [member]",
        "label": "Sales Rebates And Product Returns In U.S. Market [Member]",
        "documentation": "Sales rebates and product returns in U.S. market."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total selling, general and administrative expense",
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, general and administrative expense",
        "negatedLabel": "Selling, general, and administrative expenses"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "asnd_ShareBasedPaymentArrangementAwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ShareBasedPaymentArrangementAwardTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Share based Payment Arrangement, Award type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
      "http://ascendispharma.com/20260331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates accounted for using equity method",
        "terseLabel": "Share of profit/(loss) of associates",
        "negatedTerseLabel": "Share of (profit)/loss of associates"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "asnd_SharePriceAppliedForValuation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharePriceAppliedForValuation",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "Share Price Applied For Valuation",
        "documentation": "Share price applied for valuation."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Measurement Input [Member]",
        "documentation": "Share price measurement input [member]."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceOfEntity": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharePriceOfEntity",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Of Entity",
        "documentation": "Share price of entity.",
        "terseLabel": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareRepurchaseProgramAndRSUNetSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ShareRepurchaseProgramAndRSUNetSettlementMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program and RSU Net Settlement [member]",
        "label": "Share Repurchase Program and RSU Net Settlement [member]",
        "documentation": "Share repurchase program and RSU net settlement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ShareRepurchaseProgramMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program.",
        "label": "Share Repurchase Program [member]",
        "terseLabel": "Share Repuchase Program [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharebasedPaymentArrangementAwardTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Payment Arrangement, Award type [Domain]",
        "documentation": "Share-based payment arrangement, award type."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharebasedPaymentArrangementAwardTypeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Payment Arrangement, Award type",
        "label": "Sharebased Payment Arrangement, Award type [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Based Payment",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]",
        "documentation": "Sharebased payment arrangement, restricted stock unit, activity."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharesAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharesAgreementDescription",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Agreement Description",
        "documentation": "Shares agreement description.",
        "terseLabel": "Shares agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharesAuthorizedToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SharesAuthorizedToRepurchase",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized to repurchase",
        "label": "Shares Authorized To Repurchase",
        "documentation": "Shares authorized to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates",
        "terseLabel": "Common stocks non-diluted basis",
        "verboseLabel": "Shares held"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r215",
      "r250"
     ]
    },
    "asnd_ShortTermBorrowingOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ShortTermBorrowingOther",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Borrowing, Other",
        "documentation": "Short term borrowing, other",
        "terseLabel": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "asnd_ConvertibleNotesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "asnd_SignificantEventsInTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SignificantEventsInTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant events in the reporting period.",
        "label": "Significant Events in the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodLineitems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SignificantEventsInTheReportingPeriodLineitems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period LineItems",
        "documentation": "Significant events in the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SignificantEventsInTheReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period Table",
        "documentation": "Significant Events In The Reporting Period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SignificantEventsInTheReportingPeriodTextBlock",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/SignificantEventsInTheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Events In the Reporting Period",
        "label": "Significant Events In The Reporting Period [Text Block]",
        "documentation": "Significant Events In The Reporting Period Text Block."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StockRepurchaseProgramAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "StockRepurchaseProgramAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program Authorized",
        "documentation": "Stock repurchase program authorized.",
        "terseLabel": "Share repurchase program authorized amount"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StockRepurchaseProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "StockRepurchaseProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program Authorized Amount",
        "documentation": "Stock repurchase program authorized amount.",
        "terseLabel": "Share repurchase program authorized amount"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StockRepurchaseProgramRemainingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "StockRepurchaseProgramRemainingAmount",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program Remaining Amount",
        "documentation": "Stock repurchase program remaining amount.",
        "terseLabel": "Stock repurchase programe remaining amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary of Significant Accounting Policies [abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TaxEffectFromDeferredTaxAssetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TaxEffectFromDeferredTaxAssetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantAccountingJudgmentsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets recognized",
        "label": "Tax Effect From Deferred Tax Asset Recognized",
        "documentation": "Tax effect from deferred tax asset recognized."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of tax losses",
        "terseLabel": "Tax deductible losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r172"
     ]
    },
    "asnd_TaxLossesCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TaxLossesCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Losses Carryforwards.",
        "label": "Tax Losses Carryforwards",
        "verboseLabel": "Tax losses carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodScheduleOfSpecificationOfDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised",
        "negatedLabel": "Other temporary differences, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Total for all associates [member]; Total for all subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "asnd_ThirdPartyInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "ThirdPartyInvestorsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party investors.",
        "label": "Third Party Investors [Member]",
        "terseLabel": "Third Party Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r301"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r301"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r71",
      "r86",
      "r95",
      "r161",
      "r280",
      "r282",
      "r330"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and accrued expenses",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r310",
      "r338"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total trade and other payables",
        "terseLabel": "Trade payables",
        "label": "Trade and other payables",
        "verboseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtAmortisedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Trade payables and accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "terseLabel": "Trade receivables from associate",
        "verboseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311"
     ]
    },
    "asnd_TreasurySharesAcquiredFromThirdParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesAcquiredFromThirdParties",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Acquired From Third Parties",
        "documentation": "Treasury shares acquired from third parties.",
        "terseLabel": "Acquired from third parties (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesHoldingInPercentageAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Holding In Percentage Acquired From Third Parties",
        "documentation": "Treasury shares holding in percentage acquired from third parties.",
        "terseLabel": "Acquired from third parties (Holding in % of total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesHoldingInPercentageOfTotalOutstandingShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Holding In Percentage Of Total Outstanding Shares",
        "documentation": "Treasury shares holding in percentage of total outstanding shares.",
        "periodStartLabel": "January 1, 2026 (Holding in % of total outstanding shares)",
        "periodEndLabel": "March 31, 2026 (Holding in % of total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares holding in percentage transferred under stock incentive programs.",
        "label": "Treasury Shares Holding In Percentage Transferred under stock incentive programs",
        "terseLabel": "Transferred under stock incentive programs (Holding in % total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "asnd_TreasurySharesOfNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesOfNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Of Nominal Value",
        "documentation": "Treasury shares of nominal value.",
        "periodStartLabel": "January 1, 2026 (Nominal values)",
        "periodEndLabel": "March 31, 2026 (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TreasurySharesTransferredUnderStockIncentiveProgramNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares transferred under stock incentive program nominal value.",
        "label": "Treasury Shares Transferred Under Stock Incentive Program Nominal Value",
        "terseLabel": "Transferred under stock incentive programs (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentyEightMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Eight [member]",
        "documentation": "Two thousand and twenty eight.",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentyFiveMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Two thousand and twenty five [Member]",
        "documentation": "Two thousand and twenty five."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentyFourMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Two Thousand And Twenty four [Member]",
        "documentation": "Two thousand and twenty four."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentyNineMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Nine [Member]",
        "documentation": "Two thousand and twenty nine member.",
        "terseLabel": "2029"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentySevenMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty seven.",
        "label": "Two Thousand and Twenty seven [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentySixMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Two Thousand And Twenty six [Member]",
        "documentation": "Two thousand and twenty six."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "TwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Two Thousand And Twenty Three [Member]",
        "documentation": "Two thousand and twenty three."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r87",
      "r88",
      "r89",
      "r90",
      "r99",
      "r105",
      "r106",
      "r181"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r87",
      "r88",
      "r89",
      "r90",
      "r99",
      "r105",
      "r106",
      "r181"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r194"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r194"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "UnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. SKYTROFA.",
        "label": "United States Skytrofa [member]",
        "terseLabel": "U.S. SKYTROFA [member]",
        "verboseLabel": "SKYTROFA [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "UnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. YORVIPATH.",
        "terseLabel": "U.S. YORVIPATH [member]",
        "label": "United States Yorvipath [member]",
        "verboseLabel": "YORVIPATH [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r327"
     ]
    },
    "ifrs-full_UnobservableInputsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnobservableInputsDomain",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r327"
     ]
    },
    "asnd_VestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "VestingMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingOfSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "VestingOfSharesAxis",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Shares [Axis]",
        "documentation": "Vesting of shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VisenPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "VisenPharmaceuticalsMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Visen Pharmaceuticals [Member]",
        "verboseLabel": "Visen Pharmaceuticals [Member]",
        "documentation": "Visen Pharmaceuticals Member",
        "terseLabel": "VISEN [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_Warrant1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "Warrant1Member",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [member]",
        "label": "Warrant1 [member]",
        "documentation": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Current",
        "label": "Weighted Average Duration Of Marketable Securities Current Explanatory",
        "documentation": "Weighted average duration of marketable securities current."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities",
        "label": "Weighted Average Duration Of Marketable Securities Explanatory",
        "documentation": "Weighted average duration of marketable securities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Noncurrent",
        "label": "Weighted Average Duration Of Marketable Securities Noncurrent Explanatory",
        "documentation": "Weighted average duration of Marketable securities noncurrent explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the period",
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the period",
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Weighted average exercise price of other equity instruments vested in sharebased payment arrangement",
        "documentation": "Weighted average exercise price of other equity instruments vested in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureEarningsPerShareSummaryOfEarningsAndShareDataUsedInTheBasicAndDilutedEarningsPerShareCalculationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares used for calculation (basic and diluted)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "verboseLabel": "Weighted average number of ordinary shares for the purposes of basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "asnd_YUVIWELMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20260331",
     "localname": "YUVIWELMember",
     "presentation": [
      "http://ascendispharma.com/20260331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "YUVIWEL [Member]",
        "documentation": "YUVIWEL.",
        "terseLabel": "YUVIWEL [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2025-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20B&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "30A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "129",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_129&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "164",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "178",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "178",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "179",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "184",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_184&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "186",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "190",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_v&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "218",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "223",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "250",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "56A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_60&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "64A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "72",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "88",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "89",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2026-01-01",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.49",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_41&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_m&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_90&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "193",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "193",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_20_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
